2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 843

The Role of Personality in Patients with Fibromyalgia
Abstract Number: 506

The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol
Abstract Number: 1377

The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 2648

The SLE Risk Variant, Reference Single Nucleotide Polymorphism (rs)10499197, Upstream of Tumor Necrosis Factor Alpha-Induced Protein 3 (TNFAIP3) Modulates Enhancer Function and TNFAIP3 Gene Expression
Abstract Number: 1919

The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Abstract Number: 2847

The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout
Abstract Number: 2632

The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Abstract Number: 896

The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis
Abstract Number: 453

The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis
Abstract Number: 19

The Transcription Factor Specificity Protein 1 up-Regulates IL-21 Receptor Expression on B Cells in Rheumatoid Arthritis Leading to Altered Cytokine Production and Maturation
Abstract Number: 271

The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Abstract Number: 1983

The Types of Stress That Appear to Aggravate the Symptoms of Fibromyalgia
Abstract Number: 159

The Use of “Fibromyalgia Rapid Screening Tool” for Detection of Fibromyalgia in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Abstract Number: 2380

The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Abstract Number: 2893

The Use of Natural Language Processing to Identify, Retrieve, Report, and Correct Observational Data on US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].